Product Details:

CasNo： 3093-35-4

Molecular Formula： C24H32ClFO5

Appearance： White to off-white Powder

Packing： Bottle

Throughput： 100KG/Month

Purity： 99%

Halcinonide 

CAS：3093‑35‑4

Brand name：HALOG®

Drug class：High‑potency topical synthetic corticosteroid (Group II super‑potent topical steroid) 

✅ Official Indication

Halcinonide 0.1% cream / ointment / topical solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid‑responsive dermatoses.

Common clinical conditions：atopic dermatitis, contact dermatitis, neurodermatitis, eczema, limited plaque psoriasis, lichen planus, discoid lupus erythematosus, hypertrophic scars and other non‑infectious sub‑acute and chronic skin disorders。 Route: For topical dermatological use only. Not for ophthalmic, oral or intravaginal application

 

📄 Detailed Product English Description

Halcinonide is a high‑potency synthetic fluorinated topical corticosteroid. Chemically it is 21‑Chloro‑9‑fluoro‑11β,16α,17‑trihydroxypregn‑4‑ene‑3,20‑dione cyclic 16,17‑acetal with acetone. It exerts anti‑inflammatory, antipruritic, immunosuppressive and vasoconstrictive pharmacological effects via binding to cytoplasmic glucocorticoid receptors. Upon receptor activation, it modulates nuclear gene transcription: up‑regulating anti‑inflammatory lipocortin proteins and suppressing pro‑inflammatory mediators including prostaglandins, leukotrienes, multiple cytokines and chemokines. It reduces vascular permeability, inhibits inflammatory cell infiltration and epidermal hyperproliferation, thereby alleviating skin erythema, swelling, exudation, pruritus and lichenification. Halcinonide is commercially formulated as 0.1% ointment, cream and topical solution. It penetrates intact skin; percutaneous absorption increases significantly across inflamed, abraded skin or under occlusive dressing. Systemic absorption may suppress the hypothalamic‑pituitary‑adrenal (HPA) axis upon extensive or long‑term use. Recommended administration: apply thin film onto affected skin two to three times daily. Occlusive dressing may be adopted for refractory lesions such as psoriasis under physician supervision. Therapy should be discontinued when clinical improvement is achieved to avoid local steroid‑related adverse effects.

Safety brief note

Adverse reactions may include local skin burning, stinging, pruritus, skin atrophy, telangiectasia, striae, hypertrichosis and folliculitis with prolonged use. Percutaneous systemic absorption may cause HPA‑axis suppression. Contraindicated in bacterial, fungal, viral and parasitic infectious skin diseases. Avoid application on facial skin for long periods. Use caution in pregnancy, lactation and pediatric populations.